IRIS
Mancuso, Maria Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.305
NA - Nord America 747
SA - Sud America 495
EU - Europa 184
AF - Africa 36
Totale 2.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 685
SG - Singapore 603
BR - Brasile 391
VN - Vietnam 326
CN - Cina 223
AR - Argentina 50
IT - Italia 41
ID - Indonesia 38
HK - Hong Kong 36
FR - Francia 28
DE - Germania 24
BD - Bangladesh 19
EC - Ecuador 19
GB - Regno Unito 18
MX - Messico 17
CA - Canada 15
FI - Finlandia 13
IQ - Iraq 12
MQ - Martinica 11
RU - Federazione Russa 10
VE - Venezuela 10
CO - Colombia 9
UA - Ucraina 9
IE - Irlanda 7
NL - Olanda 7
AT - Austria 6
EG - Egitto 6
ZA - Sudafrica 6
IN - India 5
MY - Malesia 5
PK - Pakistan 5
PL - Polonia 5
TN - Tunisia 5
TR - Turchia 5
CL - Cile 4
IL - Israele 4
JM - Giamaica 4
JP - Giappone 4
MA - Marocco 4
NG - Nigeria 4
PY - Paraguay 4
SE - Svezia 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
KE - Kenya 3
LT - Lituania 3
NI - Nicaragua 3
OM - Oman 3
PE - Perù 3
SN - Senegal 3
UY - Uruguay 3
UZ - Uzbekistan 3
BO - Bolivia 2
GT - Guatemala 2
NP - Nepal 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
ES - Italia 1
ET - Etiopia 1
HR - Croazia 1
KH - Cambogia 1
KR - Corea 1
LB - Libano 1
MD - Moldavia 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 2.767
Salva come PNG Salva come JPEG
Città #
Singapore 167
San Jose 147
Ashburn 121
Ho Chi Minh City 120
Beijing 109
Dallas 87
Hanoi 64
Hong Kong 36
Wilmington 33
Santa Clara 25
The Dalles 25
São Paulo 22
Los Angeles 19
Da Nang 17
Haiphong 17
Assago 16
Chandler 15
Helsinki 13
Thái Bình 13
Curitiba 12
San Mateo 12
Buffalo 11
Fort-de-France 11
Ann Arbor 10
New York 10
Rio de Janeiro 10
Thái Nguyên 10
Hải Dương 9
Jakarta 9
Brasília 8
Buenos Aires 8
Mexico City 8
Guayaquil 7
Leawood 7
Orem 7
Porto Alegre 7
Shanghai 7
Biên Hòa 6
Boardman 6
Can Tho 6
Dublin 6
Frankfurt am Main 6
Amsterdam 5
Baghdad 5
Belo Horizonte 5
Campinas 5
Dhaka 5
Hillsboro 5
Lawrence 5
Princeton 5
Ribeirão Preto 5
Toronto 5
Uberlândia 5
Woodbridge 5
Benin City 4
Cairo 4
Contagem 4
Duque de Caxias 4
Ha Long 4
Istanbul 4
Johannesburg 4
Manaus 4
Manchester 4
Milan 4
Montreal 4
Nha Trang 4
Paris 4
Posadas 4
Quito 4
Vila Velha 4
Warsaw 4
Anápolis 3
Bandung 3
Caxias do Sul 3
Columbus 3
Dakar 3
Fortaleza 3
Guarulhos 3
Itaquaquecetuba 3
Kyiv 3
Limeira 3
Lissone 3
Lấp Vò 3
Maceió 3
Managua 3
Naples 3
North Kansas City 3
Nova Iguaçu 3
Passo Fundo 3
Praia Grande 3
Santo André 3
Santo Domingo 3
Tashkent 3
Tunis 3
Al Mansurah 2
Asunción 2
Atlanta 2
Baku 2
Barquisimeto 2
Boston 2
Totale 1.468
Salva come PNG Salva come JPEG
Nome #
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 85
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 84
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy 68
Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A 60
Uniportal and three-portal video-assisted thoracic surgery lobectomy: analysis of the Italian video-assisted thoracic surgery group database 58
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 58
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients 57
What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry 56
Severe hemophilia with mild bleeding phenotype : molecular characterization and global coagulation profile 46
Predicting a Prolonged Air Leak After Video-Assisted Thoracic Surgery, Is It Really Possible? 44
Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents 43
Peri-operative and post-operative management of haemophiliac patients without inhibitors 41
Ageing successfully with haemophilia : A multidisciplinary programme 41
Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study 38
Association study between XRCC1 gene polymorphisms and sporadic amyotrophic lateral sclerosis 38
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 37
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A 36
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A : a patient-level meta-analysis 36
Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia 36
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors 35
Peri-operative and post-operative management of haemophiliac patients with inhibitors 34
Orthopaedic management of haemophilia arthropathy of the ankle 34
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders 34
Arteriovenous fistula as stable venous access in children with severe haemophilia 33
Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases 32
Global Emerging HEmophilia Panel (GEHEP): a multinational collaboration for Advancing hemophilia research and treatment 32
Deep intronic variations may cause mild hemophilia A 32
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors 32
Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis 32
F8 mRNA studies in haemophilia A patients with different splice site mutations 31
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype 31
A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients : evidence for a founder effect 31
A catastrophic case of skin gangrene 30
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy 30
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial 30
Dental surgery in inherited bleeding disorders with minimal factor support: commentary 30
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study 29
Synoviorthesis in haemophilia patients with inhibitors 29
Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients 29
Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention 29
Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A 29
Venous access in haemophilic children: choice and management 28
Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs : a review of 116 procedures at a single institution 28
Increased VEGF levels in a case of papillary tumor of the pineal region with intracranial hemorrhage: A potential surrogate indicator of tumor angiogenesis and aggressiveness? 28
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 28
Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A 28
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management 28
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers 28
Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry 27
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors 27
Applying a deliberation model to the analysis of consultations in haemophilia: Implications for doctor-patient communication 27
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study 27
Integrated postural analysis in children with haemophilia 26
Platelets from glioblastoma patients promote angiogenesis of tumor endothelial cells and exhibit increased VEGF content and release 26
Factor VIII products and inhibitor development in severe hemophilia A 26
Congenital afibrinogenemia 26
Implicazioni economiche del trattamento dei pazienti emofilici con inibitori: una revisione sistematica della letteratura 26
Handwriting Analysis in Children and Adolescents with Hemophilia : A Pilot Study 26
Prevention of arthropathy in haemophilia: prophylaxis 26
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study 24
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up 24
Results from a large multinational clinical trial (guardian (TM) 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy 24
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors 24
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease 24
Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients 24
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors 23
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C 23
Polypharmacy in older adults with severe haemophilia 23
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study 23
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters 23
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 23
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis 22
Synovitis and joint health in patients with haemophilia: Statements from a European e‐Delphi consensus study 22
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access 22
Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement 22
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 21
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 21
Radiosynoviorthesis in children with haemophilia 20
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A 20
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing 20
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort 20
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: Considerations on the differentiation between the 2 circulating anticoagulants 19
Muscle function deterioration in patients with haemophilia: Prospective experience from Costa Rica 19
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice 18
Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication 17
The thrombin generation assay distinguishes inhibitor from non‐inhibitor patients with severe haemophilia A 17
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice 17
Investigational drugs for coagulation disorders 17
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study 15
The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH 15
Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents 14
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A 14
Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients 13
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study 12
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors 11
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis 9
Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B 8
Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients 4
Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications 2
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors 2
Totale 2.871
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 0 6
2021/202228 1 0 0 7 0 0 2 6 1 3 7 1
2022/202350 12 1 5 4 2 4 0 5 11 6 0 0
2023/202445 2 7 8 1 1 6 0 0 2 0 9 9
2024/202580 8 0 1 2 1 7 4 5 10 30 5 7
2025/20262.603 211 121 278 571 194 85 345 269 236 161 76 56
Totale 2.873